As a consequence, MET inhibitors demonstrate clinical efficacy when initially administered to glioblastoma patients; however, unfortunately, the acquired resistance to these agents frequently ensues and hampers their prolonged use [27]. The gene discussed is MET; the disease is glioblastoma.